Liid Pharmaceuticals, Inc

Liid Pharmaceutical, Inc. is committed to develop ASOs by leveraging our proprietary BROTHERS (BRO) technology, which thermodynamically and kinetically enhances the efficacy and mitigates safety profiles by reducing off-target effects. We strongly believe that ASOs with BRO technology can have potential uses in the treatment of a range of serious and life-threatening human diseases. Liid Pharmaceuticals is actively developing a diverse pipeline to address unmet medical needs, such as Gaucher disease (lysosomal storage diseases), MASH (metabolic dysfunction-associated steatotic liver disease, NASH) and heart failure, etc. We are also looking forward to collaborating with academia/biotech/pharma.